CDKN2A缺失对食管腺癌演变的影响取决于背景和时间。 - Suppr

Suppr

超能文献

Effects of CDKN2A loss on evolution of esophageal adenocarcinoma depend on context and time.

出版信息

Nat Cancer. 2025 Jan;6(1):22-23. doi: 10.1038/s43018-024-00877-z.

DOI:10.1038/s43018-024-00877-z

PMID:39775032

Abstract

摘要

相似文献

Effects of CDKN2A loss on evolution of esophageal adenocarcinoma depend on context and time.CDKN2A缺失对食管腺癌演变的影响取决于背景和时间。

Nat Cancer. 2025 Jan;6(1):22-23. doi: 10.1038/s43018-024-00877-z.

Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.MTAP与p16/CDKN2A表达在胃食管癌发生过程中的一致性缺失：食管非侵袭性前驱病变中纯合缺失的证据及治疗意义

Am J Surg Pathol. 2005 Nov;29(11):1497-504. doi: 10.1097/01.pas.0000170349.47680.e8.

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.食管癌演变过程中CDKN2A及其他9p21基因缺失的情境依赖性效应。

Nat Cancer. 2025 Jan;6(1):158-174. doi: 10.1038/s43018-024-00876-0. Epub 2025 Jan 3.

p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.CDKN2A启动子甲基化导致的p16失活发生在巴雷特食管肿瘤进展的早期。

Gastroenterology. 2002 Apr;122(4):1113-21. doi: 10.1053/gast.2002.32370.

CDKN2A-p16 Deletion and Activated KRAS Drive Barrett's-Like Gland Hyperplasia-Metaplasia and Synergize in the Development of Dysplasia Precancer Lesions.CDKN2A-p16 缺失和激活的 KRAS 驱动 Barrett 样腺体增生-化生，并协同促进异型增生癌前病变的发展。

Cell Mol Gastroenterol Hepatol. 2024;17(5):769-784. doi: 10.1016/j.jcmgh.2024.01.014. Epub 2024 Jan 29.

Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma.整合性全基因组关联分析 CDKN2A 和 TP53 单核苷酸多态性与食管腺癌风险的关系。

Carcinogenesis. 2014 Dec;35(12):2740-7. doi: 10.1093/carcin/bgu207. Epub 2014 Oct 3.

High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma.食管发育不良和腺癌患者巴雷特化生中高分辨率基因组改变。

Int J Cancer. 2019 Nov 15;145(10):2754-2766. doi: 10.1002/ijc.32351. Epub 2019 May 2.

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.非甾体抗炎药可调节CDKN2A、TP53以及进展为食管腺癌的DNA含量风险。

PLoS Med. 2007 Feb;4(2):e67. doi: 10.1371/journal.pmed.0040067.

Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.原发性人类食管癌中CDKN2B和CDKN2A的基因内突变。

Hum Mol Genet. 1995 Oct;4(10):1883-7. doi: 10.1093/hmg/4.10.1883.

Development of esophageal squamous cell cancer in patients with FAMMM syndrome: Two clinical reports.FAMMM综合征患者食管鳞状细胞癌的发生：两份临床报告。

Eur J Med Genet. 2020 Mar;63(3):103840. doi: 10.1016/j.ejmg.2020.103840. Epub 2020 Jan 7.

本文引用的文献

Somatic variation in normal tissues: friend or foe of cancer early detection?正常组织中的体细胞变异：癌症早期检测的敌是友？

Ann Oncol. 2022 Dec;33(12):1239-1249. doi: 10.1016/j.annonc.2022.09.156. Epub 2022 Sep 23.

Comparative assessment of genes driving cancer and somatic evolution in non-cancer tissues: an update of the Network of Cancer Genes (NCG) resource.比较非癌组织中驱动癌症和体细胞进化的基因：癌症基因网络 (NCG) 资源的更新。

Genome Biol. 2022 Jan 26;23(1):35. doi: 10.1186/s13059-022-02607-z.

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.9p21 缺失导致肿瘤免疫微环境寒冷，并对免疫检查点治疗产生原发性耐药。

Nat Commun. 2021 Sep 23;12(1):5606. doi: 10.1038/s41467-021-25894-9.

Esophageal carcinoma.食管癌

N Engl J Med. 2014 Dec 25;371(26):2499-509. doi: 10.1056/NEJMra1314530.

Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.9p21的等位基因缺失和CDKN2/p16基因的突变在巴雷特食管的肿瘤进展过程中作为早期病变出现。

Oncogene. 1996 Nov 7;13(9):1867-73.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验